A double-blind, dose-finding study for the i.v. bolus injection of SUN9216 (Modified tissue plasminogen activator) in acute myocardial infarction: Clinical late phase II study

Japanese Pharmacology and Therapeutics

Volumn 25, Issue 1, 1997, Pages 245-267

  Yui, Yoshiki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LANOTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION; MALE; PHASE 2 CLINICAL TRIAL; PLASMINOGEN ACTIVATION;

EID: 0030931096     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Collen D et al : Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 71 : 216-219, 1988
2. Larsen GR et al : Pharmacokinetics and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood 73 : 1842-1850, 1989
3. Reimer KA et al : The wavefront phenomenon of ischemic cell death ; I. myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 56 : 786-794, 1977
4. Mathey DG et al : Zeitabhängigkeit der Myokarderhaltung nach Thrombolyse. Dtsche Med Wschr 110 : 1681-1685, 1985
5. Hochman JS, Choo H : Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 75 : 299-306, 1987
6. Sheehan FH et al : The effect of intravenous thrombolytic therapy on left ventricular function ; A report on tissue-type plasminogen activator and streptokinase from the thrombolysis in myocardial infarction (TIMI phase I) trial. Circulation 75 : 817-829, 1987
7. Werf FV, Arnold AER : Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. Br Med J 297 : 1374-1379, 1988
8. Topol EJ e.t al : Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction ; Improved timing, thrombolytic efficacy and ventricular function. JACC 10 : 1173-1177, 1987
9. National Heart Foundation of Austraria Coronary Thrombolysis Group : Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet i : 203-207, 1988
10. White HD et al : Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. New Engl J Med 320 : 817-821, 1989
11. Gang ES et al : Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. New Engl J Med 321 : 712-716, 1989
12. Topol EJ et al : A randomized trial of late reperfusion therapy for acute myocardial infarction. Circulation 85 : 2090-2099, 1992
13. Mueller HS et al : Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction ; Analyses of patient sub-groups in the thormbolysis in myocardial infarction (TIMI) trial, phase II. Circulation 85 : 1254-1264, 1992
14. The GUSTO Investigators : An international randomaized trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med 329 : 673-682, 1993
15. The GUSTO Angiographic Investigators : The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. New Engl J Med 329 : 1615-1622, 1993
16. Seifried E et al : Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemostas 61 : 497-501, 1989
17. Seifried E et al : Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneim Forsch/Drug Res 38 : 418-422, 1988
18. Chesebro JH et al : Thrombolysis in myocardial infarction (TIMI) trial, phase I ; A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76 : 142-154, 1987